Additional Ring Containing Patents (Class 544/211)
  • Patent number: 11078412
    Abstract: The present invention relates to a method of analyzing a polyamine having a plurality of amino groups in the same molecule or a monoamine having an amino group and a phenolic hydroxyl group in the same molecule on the basis of the measurement result of the intensity of excimer fluorescence emitted as a result of the derivatization of the polyamine or the monoamine with a fluorescence derivatization reagent having a pyrene group. The method is characterized in that the fluorescence derivatization reagent comprises 2-chloro-4-methoxy-6-(4-(pyren-1-yl) butoxy)-1, 3, 5-triazine represented by the formula (2).
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: August 3, 2021
    Assignees: Shimadzu Corporation, Shizuoka Prefecture Public University Corporation
    Inventors: Makoto Ogaito, Azusa Uchida, Kenichiro Todoroki, Tatsuki Nakano, Toshimasa Toyo'Oka
  • Patent number: 10065941
    Abstract: The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic activity. A compound of Formula (I): wherein Ra and Rb, and Rd and Re are taken together to form oxo or the like; R4a and R4b are hydrogen or the like; n is 1 or the like; R2 is aryl or the like; s and s? is 0 or the like; R9 and R9? are halogen or the like; R20a and R20b are hydrogen, alkyl or the like; u is 1 to 4; R13 is hydrogen or the like, or its pharmaceutically acceptable salt.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: September 4, 2018
    Assignee: SHIONOGI & CO., LTD.
    Inventor: Hiroyuki Kai
  • Patent number: 9845297
    Abstract: The present invention relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, and reducing the risk of microbial infections in humans and animals.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: December 19, 2017
    Assignee: Melinta Therapeutics, Inc.
    Inventors: Erin M. Duffy, Ashoke Bhattacharjee, Hardwin O'Dowd, Marco DeVivo, Yanming Du, Sandra Sinishtaj, Yuanqing Tang, Brian T. Wimberly
  • Patent number: 9688668
    Abstract: The invention relates to inhibitors of Sphingosine Kinase enzymatic activity, and methods of treating diseases and disorders by administering inhibitors of Sphingosine Kinase enzymatic activity.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: June 27, 2017
    Assignee: University of Virginia Patent Foundation
    Inventors: Webster L. Santos, Kevin R. Lynch, Timothy L. Macdonald, Andrew Kennedy, Yugesh Kharel, Mithun Rajendra Raje, Joseph Houck
  • Patent number: 9115121
    Abstract: The present invention relates to compounds corresponding to formula (I) in which: —R1 represents a substituted phenyl; —R2 represents: —a substituted phenyl; —a heteroaromatic group, the said group being unsubstituted or substituted one or more times; —R3 represents a group Alk; —R4 represents a hydrogen atom or a (C1-C4)alkyl; —R5 represents a hydrogen atom, a (C3-C6)cycloalkyl or a (C1-C4)alkyl-O-Alk; —or alternatively R4 and R5, together with the nitrogen atom to which they are attached, constitute a heterocyclic radical chosen from: azetidin-1-yl, pyrrolidin-1-yl, piperid-1-yl, morpholin-4-yl; —R6 represents a group —COOAlk, a group —CONH2 or a group —NHSO2Alk; —Alk represents a (C1-C4)alkyl, which is unsubstituted or substituted one or more times with a halogen atom; in the form of the base or of an acid-addition salt. Preparation process and diagnostic and therapeutic use.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: August 25, 2015
    Assignee: Sanofi
    Inventors: Joelle Arnaud, Martine Artiaga, Francis Barth, Laurent Hortala, Serge Martinez, Pascale Roux
  • Patent number: 9085559
    Abstract: A novel heterocyclic compound belonging to ‘triazine-aryl-bis-indoles’, useful for the treatment of asthma. The pathway by which this compound inhibits asthma is also demonstrated. The present invention also provides a process for the preparation of above compounds and their derivatives are presented.
    Type: Grant
    Filed: December 31, 2010
    Date of Patent: July 21, 2015
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Vasanta Madhava Sharma Gangavaram, Jhillu Singh Yadav, Radha Krishna Palakodety, Arun Bandyopadhyay, Siddhartha Roy, Santu Bandyopadhyay, Rakesh Kamal Johri, Subhash Chander Sharma, Balaram Ghosh, Mabalirajan Ulaganathan, Sakshi Balwani, Bholanath Paul, Ashok Kumar Saxena
  • Patent number: 9018209
    Abstract: The present invention relates to compounds according to the formula I: Where Ra is H or an optionally OH-substituted C1-C3 alkyl; R1 is OR1, an optionally substituted C4-12 carbocyclic group which may be saturated or unsaturated (including aromatic) or an optionally substituted heterocyclic group; R1 is an optionally substituted C1-C14 hydrocarbyl group or an optionally substituted heterocyclic group; R2, R3 and R4 are each independently H, an optionally substituted C1-C4 alkyl group (preferably CH3, CH2CH3 or CF3), halogen (preferably F, Cl, Br), OR, CN, NO2, a C1-C6 thioether, a C1-C6 thioester group, an optionally substituted CO2R group, an optionally substituted COR group or an optionally substituted OCOR group (preferably R4 is H); R is H or an optionally substituted C1-C6 alkyl group; RHET is an optionally substituted heterocyclic group; and pharmaceutically acceptable salts, solvates or polymorphs thereof.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: April 28, 2015
    Assignee: Yale University
    Inventors: William L. Jorgensen, Juliana Ruiz-Caro, Andrew D. Hamilton
  • Patent number: 9012582
    Abstract: A resin with a favorable index of refraction and transparency even without using heavy atoms or inorganic oxide fine particles by means of a polymerizable monomer having a 1,3,5-triazine ring represented by formula 1. (In formula 1: A is a group represented by formula 2, (in formula 2: R1 represents a hydrogen atom or a methyl group, T represents an alkylene having 1-10 carbon atoms, and R2 represents O or NH), and B1 and B2 are each independently groups represented by formula 3, formula 4, or formula 5 (in formulas 3-5: R3, R4, and R5 represent an alkyl group having 1-10 carbon atoms, an aryl group, or an aryloxy group, n1 and n3 are integers from 0-5, and n2 is an integer from 0-7, however when there are at least two of each of R3, R4, and R5, these may be the same or different from each other).
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: April 21, 2015
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Kenichi Osawa, Takuro Oda
  • Patent number: 8952150
    Abstract: Disclosed are compounds for inhibiting prostaglandin transporter (PGT) activity, pharmaceuticals compositions including the compounds, and methods of treating subjects using the compounds.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: February 10, 2015
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Victor L. Schuster, Yuling Chi, Andrew S. Wasmuth, Richard S. Pottorf, Gary L. Olson
  • Patent number: 8952001
    Abstract: The invention relates to amino-heteroaryl derivatives having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the treatment of pain, such as neuropathic pain or inflammatory pain.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: February 10, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Simon James Anthony Grove, Angus John Morrison, Craig Jamieson, Ronald Palin, John Kinnaird Ferguson Maclean
  • Publication number: 20150011751
    Abstract: To provide a novel triazine derivative represented by the following formula (I): A triazine derivative represented by the following formula (I): wherein R1 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, a substituted or unsubstituted heterocyclic fused ring, or a substituted or unsubstituted alkynyl group, R2 represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group, R3 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, or a substituted or unsubstituted heterocyclic fused ring, R4 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, or a halogen atom, and R5 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, or R1 and R5 may be combined to form a saturated or unsaturate
    Type: Application
    Filed: March 7, 2013
    Publication date: January 8, 2015
    Inventors: Wataru Kawahata, Tokiko Asami, Masaaki Sawa, Yuko Asamitsu, Takayuki Irie, Takahiro Miyake, Takao Kiyoi
  • Patent number: 8916557
    Abstract: The present invention relates to substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: December 23, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bömer, Gerd Rühter, Carsten Schultz-Fademrecht, Dirk Kosemund, Philip Lienau
  • Publication number: 20140343061
    Abstract: The present invention relates to compounds corresponding to formula (I) in which: —R1 represents a substituted phenyl; —R2 represents: —a substituted phenyl; —a heteroaromatic group, the said group being unsubstituted or substituted one or more times; —R3 represents a group Alk; —R4 represents a hydrogen atom or a (C1-C4)alkyl; —R5 represents a hydrogen atom, a (C3-C6)cycloalkyl or a (C1-C4)alkyl-O-Alk; —or alternatively R4 and R5, together with the nitrogen atom to which they are attached, constitute a heterocyclic radical chosen from: azetidin-1-yl, pyrrolidin-1-yl, piperid-1-yl, morpholin-4-yl; —R6 represents a group —COOAlk, a group —CONH2 or a group —NHSO2Alk; —Alk represents a (C1-C4)alkyl, which is unsubstituted or substituted one or more times with a halogen atom; in the form of the base or of an acid-addition salt. Preparation process and diagnostic and therapeutic use.
    Type: Application
    Filed: December 11, 2012
    Publication date: November 20, 2014
    Inventors: Joelle Arnaud, Martine Artiaga, Francis Barth, Laurent Hortala, Serge Martinez, Pascale Roux
  • Publication number: 20140315906
    Abstract: The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).
    Type: Application
    Filed: May 21, 2012
    Publication date: October 23, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bömer, Dirk Kosemund, Philip Lienau, Gerd Rühter, Carsten Schultz-Fademrecht
  • Patent number: 8859679
    Abstract: The instant invention relates to storage stable aqueous solutions of stilbene optical brighteners with polyvinyl alcohols which can be directly used by the papermaker in that they may be diluted with water and/or be metered directly into a coating composition, to provide coated papers of a particularly high whiteness.
    Type: Grant
    Filed: April 5, 2006
    Date of Patent: October 14, 2014
    Assignee: Clariant Finance (BVI) Limited
    Inventors: Andrew Clive Jackson, Alec Stewart Tindal, Mariela Gauto
  • Publication number: 20140303167
    Abstract: The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.
    Type: Application
    Filed: August 22, 2012
    Publication date: October 9, 2014
    Applicant: LEAD DISCOVERY CENTER GMBH
    Inventors: Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann
  • Publication number: 20140288017
    Abstract: The present invention is directed to novel catechol diether compounds, pharmaceutical compositions therefrom and methods for inhibiting reverse transcriptase and treating HIV infections, especially included drug resistant strains of HIV 1 and 2 and/or secondary disease states and/or conditions which occur as a consequence of HIV infection.
    Type: Application
    Filed: October 12, 2012
    Publication date: September 25, 2014
    Inventors: William L. Jorgensen, Karen S. Anderson
  • Publication number: 20140225070
    Abstract: Provided is an organic light-emitting diode including a compound of Formula 1 below: A detailed description of a substituent in Formula 1 above is defined as described in the detailed description.
    Type: Application
    Filed: June 21, 2013
    Publication date: August 14, 2014
    Applicant: Samsung Display Co., Ltd.
    Inventors: Jun-Ha Park, Seok-Hwan Hwang, Young-Kook Kim, Hye-Jin Jung, Eun-Young Lee, Jin-O Lim, Sang-Hyun Han, Eun-Jae Jeong, Soo-Yon Kim, Jong-Hyuk Lee
  • Publication number: 20140179637
    Abstract: A compound having an antiviral activity for inhibiting release of an enveloped virus from a cell is disclosed, including methods of inhibiting release of an enveloped virus from a cell. The antiviral activity of the compound includes inhibiting formation of an associative complex or disrupting formation of an associative complex. The associative complex comprises an L-domain motif of the enveloped virus and at least one cellular polypeptide, or fragment thereof, capable of binding the L-domain motif of the enveloped virus.
    Type: Application
    Filed: December 21, 2013
    Publication date: June 26, 2014
    Applicants: The Research Foundation for The State University of New York, Northwestern University
    Inventors: Jonathan Leis, Carol Carter
  • Patent number: 8748411
    Abstract: Chemical compounds derived by in silico molecular modelling, having a well defined structure suitable for the blocking of the phosphorylation event, through the specific interaction of the chemical with the Casein Kinase 2 enzyme substrate phosphorylation domain or it's neighbourhood. This invention comprises also the pharmaceutical compositions containing such compounds, and their use in the preparation of medicines or agents for the treatment of diseases or conditions related with neoplasic processes.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: June 10, 2014
    Assignee: Centro de Ingenieria Genetica y Biotechnologia
    Inventors: Rolando Eduardo Rodriguez Fernandez, Roberto Vera Alvarez, Ania De La Nuez Veulens, Yuliet Mazola Reyes, Silvio Ernesto Perea Rodriguez, Boris Ernesto Acevedo Castro, Alexis Musacchio Lasa, Raimundo Ubieta Gómez
  • Publication number: 20140130191
    Abstract: The invention relates to a compound comprising non-peptide prokineticin receptors antagonists and agents that modulate or inhibit the activity of prokineticin receptors for use in the treatment of immune-mediated diseases of the central nervous system, peripheral nervous system and neuromuscular junctions.
    Type: Application
    Filed: June 27, 2012
    Publication date: May 8, 2014
    Applicant: FONDAZIONE I.R.C.C.S. ISTITUTO NEUROLOGICO "CARLO BESTA"
    Inventors: Rosetta Pedotti, Mohamad Abou Hamdan
  • Patent number: 8710174
    Abstract: A polymer containing a triazine ring-containing repeating unit structure represented by, for example, formula (23) or (24), which alone can achieve high heat resistance, high transparency, high refraction index, high solubility, and low volume shrinkage, without adding a metal oxide.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: April 29, 2014
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Naoya Nishimura, Taku Kato, Masaaki Ozawa, Masahiro Hida, Yasuyuki Koide
  • Publication number: 20140045852
    Abstract: The present invention relates to substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: April 18, 2012
    Publication date: February 13, 2014
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bomer, Gerd Rühter, Carsten Schultz-Fademrecht, Dirk Kosemund, Philip Lienau
  • Publication number: 20130239340
    Abstract: Tanned leather, skin or pelt is produced by non-metal tanning, comprising the step of tanning a bated hide, skin or pelt with a tanning agent (A), the tanning agent (A) being at least one compound of formula (I), wherein Hal signifies chlorine or fluorine, X signifies N or CR Y signifies hydrogen, C1-8-alkyl, C1-4-alkyl-carbonyl, C1-4-alkyl-sulphonyl or a radical of formula (Ia), or (Ib) —(—C2-3 alkylene-O—)q—H??(Ib) R signifies hydrogen or chlorine, q is 1 to 10 and M signifies hydrogen or an alkali metal cation or an ammonium cation, the ammonium cation being a protonated tertiary amine or a quaternary ammonium cation, in a tanning bath, the tanning bath having a pH of from 6 to 10 at the beginning of the tanning step.
    Type: Application
    Filed: October 25, 2011
    Publication date: September 19, 2013
    Applicant: CLARIANT FINANCE (BVI) LIMITED
    Inventors: Claus Reineking, Roberta Gamarino, Licia Trimarco, Maurizio Quaglierini, Markus Gisler, Rainer Nusser
  • Publication number: 20130227799
    Abstract: Tanned leather, skin or pelt is produced by non-metal tanning, comprising the step of tanning a bated hide, skin or pelt with a tanning agent (A), the tanning agent (A) being at least one compound of formula (I), R—NH—Y—SO2—Z??(I), wherein R signifies a radical of formula wherein Hal signifies fluorine or chlorine, X signifies N or CR1, Y signifies an aliphatic, araliphatic or aromatic hydrocarbonic bridge which may optionally be interrupted by a heteroatom or heteroatomic group, Z signifies vinyl, ?-chloroethyl, ?-phosphatoethyl or ?-sulphatoethyl R1 signifies hydrogen or Cl, in a tanning bath, the tanning bath having a pH of from 6 to 10 at the beginning of tanning step.
    Type: Application
    Filed: October 25, 2011
    Publication date: September 5, 2013
    Applicant: CLARIANT FINANCE (BVI) LIMITED
    Inventors: Claus Reineking, Roberta Gamarino, Licia Trimarco, Maurizio Quaglierini, Markus Gisler, Rainer Nusser
  • Publication number: 20130205516
    Abstract: Tanned leather, skin or pelt is produced by non-metal tanning, comprising the step of tanning a bated hide, skin or pelt with a tanning agent (A), the tanning agent (A) being at least one compound of formula (I), wherein X signifies fluorine, chlorine and/or (+NR3)0-1, wherein R is a substituted C1 to C6 alkyl group or an unsubstituted C1 to C6 alkyl group, an unsubstituted C6 to C10 aryl group or a substituted C6 to C10 aryl group or a C5 to C6 heteroaryl group, R1 signifies hydrogen, C1-8-alkyl or an alkyleneoxy radical of formula (Ia), -(—C2-3alkylene-O—)q-H??(Ia) R2 signifies hydrogen or hydroxy, m signifies 1, 2 or 3, q is of from 1 to 10, M signifies hydrogen or an alkali metal cation or an ammonium cation, the ammonium cation being a protonated tertiary amine or a quaternary ammonium cation, in a tanning bath, the tanning bath having a pH of from 6 to 10 at the beginning of tanning step.
    Type: Application
    Filed: October 5, 2011
    Publication date: August 15, 2013
    Applicant: CLARIANT FINANCE (BVI) LIMITED
    Inventors: Claus Reineking, Roberta Gamarino, Licia Trimarco, Maurizio Quaglierini, Markus Gisler, Rainer Nusser
  • Publication number: 20130198974
    Abstract: Tanned leather, skin or pelt is produced by non-metal tanning, comprising the step of tanning a bated hide, skin or pelt with a tanning agent (A), the tanning agent (A) being at least one compound of formula (I), wherein X signifies fluorine or chlorine, and/or (+NR3)0-1, wherein R is a substituted C1 to C6 alkyl group or an unsubstituted C1 to C6 alkyl group, an unsubstituted C6 to C10 aryl group or a substituted C6 to C10 aryl group or a C5 to C6 heteroaryl group.
    Type: Application
    Filed: October 5, 2011
    Publication date: August 8, 2013
    Applicant: CLARIANT FINANCE (BVI) LIMITED
    Inventors: Claus Reineking, Roberta Gamarino, Licia Trimarco, Maurizio Quaglierini, Markus Gisler, Rainer Nusser
  • Publication number: 20130190179
    Abstract: The present invention relates generally to the use of biological or chemical control agents with for controlling insects and nematodes and to methods particularly useful for combating insects or nematodes and/or increasing crop yield in plants that are at least partially resistant to one or more parasitic nematodes or insects.
    Type: Application
    Filed: October 13, 2011
    Publication date: July 25, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ruediger Hain, Gerhard Johann, Guenter Donn
  • Publication number: 20130172317
    Abstract: The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect. A pharmaceutical composition having an analgesic effect or an improving effect of urination disorder comprising a compound of the formula (I): wherein Rh and Rj are taken together to form a bond; Ra and Rb and/or Rd and Re are taken together to form oxo or the like; Rc is hydrogen, substituted or unsubstituted alkyl or the like; Rf is —(CR4aR4b)n—R2; R4a and R4b are hydrogen, substituted or unsubstituted alkyl or the like; R2 is substituted or unsubstituted cycloalkyl or the like; n is an integer of 1 to 4; —Rg is —X—R3; —X— is —O—, —S— or the like; R3 is substituted or unsubstituted cycloalkyl or the like, or its pharmaceutically acceptable salt or a solvate thereof.
    Type: Application
    Filed: August 9, 2011
    Publication date: July 4, 2013
    Inventors: Hiroyuki Kai, Takayuki Kameyama, Tohru Horiguchi, Kentaro Asahi, Takeshi Endoh, Yasuhiko Fujii, Takuya Shintani, Ken'ichiroh Nakamura, Sae Jikihara, Tsuyoshi Hasegawa, Miho Oohara, Yukio Tada, Toshikatsu Maki, Akira Iida
  • Publication number: 20130137635
    Abstract: This invention relates to tryptophan hydroxylase inhibitors, compositions comprising them, and methods of their use for the treatment, management and/or prevention of metastatic bone disease.
    Type: Application
    Filed: February 9, 2011
    Publication date: May 30, 2013
    Applicant: LEXICON PHARMACEUTICALS, INC.
    Inventor: Arthur Thomas Sands
  • Publication number: 20130131340
    Abstract: Estrogen-Related Receptor (ERR) modulating compounds and methods for synthesis of said compounds are described.
    Type: Application
    Filed: September 20, 2011
    Publication date: May 23, 2013
    Inventors: Barry Forman, Donna Yu
  • Publication number: 20130079345
    Abstract: The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase.
    Type: Application
    Filed: March 20, 2011
    Publication date: March 28, 2013
    Applicants: BAYER INTELLECTUAL PROPERTY GMBH, LEAD DISCOVERY CENTER GMBH
    Inventors: Jan Eickhoff, Peter Nussbaumer, Gerd Ruhter, Carsten Schultz-Fademrecht, Ulrich Lucking, Axel Choidas, Bert Klebl
  • Publication number: 20120316171
    Abstract: Methods and compositions for the treatment and/or management of cancer are disclosed, which comprise the use of tryptophan hydroxylase inhibitors.
    Type: Application
    Filed: November 4, 2010
    Publication date: December 13, 2012
    Inventor: Tamas Oravecz
  • Patent number: 8324249
    Abstract: The invention relates to tetrahydropyridinyl and dihydropyrrolyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X, Y, Z, R1, R2, m, and n are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: August 3, 2009
    Date of Patent: December 4, 2012
    Assignees: Purdue Pharma L.P., Shionogi & Co., Ltd.
    Inventors: Hidenori Mikamiyama, Chiyou Ni, Bin Shao, Laykea Tafesse
  • Publication number: 20120264728
    Abstract: The invention relates to amino-heteroaryl derivatives having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the treatment of pain, such as neuropathic pain or inflammatory pain.
    Type: Application
    Filed: December 20, 2010
    Publication date: October 18, 2012
    Inventors: Simon James Anthony Grove, Angus John Morrison, Craig Jamieson, Ronald Palin, John Kinnaird Ferguson Maclean
  • Publication number: 20120214811
    Abstract: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: August 27, 2010
    Publication date: August 23, 2012
    Inventors: Ignacio Aliagas, Stefan Gradl, Janet Gunzner, Simon Mathieu, Rebecca Pulk, Joachim Rudolph, Zhaoyang Wen
  • Publication number: 20120190683
    Abstract: N-Azinyl-N?-aryl ureas and thioureas derivatives are effective at controlling insects.
    Type: Application
    Filed: July 22, 2011
    Publication date: July 26, 2012
    Applicant: DOW AGROSCIENCES LLC
    Inventors: Noormohamed M. Niyaz, Ricky Hunter, Timothy C. Johnson, Tony K. Trullinger, Annette V. Brown, Kristy Bryan
  • Publication number: 20120190684
    Abstract: N-Azinyl-N?-aryl ureas and thioureas derivatives are effective at controlling insects.
    Type: Application
    Filed: July 22, 2011
    Publication date: July 26, 2012
    Applicant: DOW AGROSCIENCES LLC
    Inventors: Noormohamed M. Niyaz, Ricky Hunter, Timothy C. Johnson, Tony K. Trullinger, Annette V. Brown, Kristy Bryan
  • Publication number: 20120142878
    Abstract: A resin with a favorable index of refraction and transparency even without using heavy atoms or inorganic oxide fine particles by means of a polymerizable monomer having a 1,3,5-triazine ring represented by formula 1. (In formula 1: A is a group represented by formula 2, (in formula 2: R1 represents a hydrogen atom or a methyl group, T represents an alkylene having 1-10 carbon atoms, and R2 represents O or NH), and B1 and B2 are each independently groups represented by formula 3, formula 4, or formula 5 (in formulas 3-5: R3, R4, and R5 represent an alkyl group having 1-10 carbon atoms, an aryl group, or an aryloxy group, n1 and n3 are integers from 0-5, and n2 is an integer from 0-7, however when there are at least two of each of R3, R4, and R5, these may be the same or different from each other).
    Type: Application
    Filed: August 6, 2010
    Publication date: June 7, 2012
    Inventors: Kenichi Osawa, Takuro Oda
  • Publication number: 20120129862
    Abstract: The present invention relates to certain novel compounds of Formula (I): and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.
    Type: Application
    Filed: May 23, 2011
    Publication date: May 24, 2012
    Inventors: Steven J. Coats, Alexey B. Dyatkin, Wei He, Joseph Lisko, Tamara A. Miskowski, Janet L. Ralbovsky, Mark J. Schulz
  • Patent number: 8153788
    Abstract: Compounds of the formula (I) or salts thereof, in which in which R1 is an optionally substituted amino group or analogous group, and R2 to R7 are each as described herein, are suitable as herbicides and crop growth regulators. The compounds (I) can be prepared by the processes described, via intermediates including novel intermediates for example of the formula (III).
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: April 10, 2012
    Inventors: Hartmut Ahrens, Hansjörg Dietrich, Thomas Auler, Martin Hills, Heinz Kehne, Dieter Feucht, Stefan Herrmann, Kristian Kather, Stefan Lehr
  • Publication number: 20120058985
    Abstract: The disclosed compounds are useful in the treatment of mammalian cancers and especially human cancers. Compounds, pharmaceutical compositions, and methods of Formula I are disclosed: or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer, or tautomer thereof.
    Type: Application
    Filed: April 29, 2011
    Publication date: March 8, 2012
    Applicant: DECIPHERA PHARMACEUTICALS, LLC
    Inventors: DANIEL L. FLYNN, MICHAEL D. KAUFMAN
  • Patent number: 8106194
    Abstract: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A pyrrolopyrimidine or pyrrolotriazine derivative substituted with a carbamoyl group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
    Type: Grant
    Filed: January 6, 2005
    Date of Patent: January 31, 2012
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Atsuro Nakazato, Taketoshi Okubo, Dai Nozawa, Tomoko Tamita, Ludo E. J. Kennis
  • Publication number: 20120009151
    Abstract: Disclosed herein are novel triazines and related compounds, the synthesis thereof, and compositions, including pharmaceutical compositions, comprising the novel triazines and related compounds. Such novel triazines and related compounds function to inhibit or block entry of viruses of the Flaviviridae family, including Hepatitis C virus (HCV), into cells that are susceptible to virus infection. These compounds are useful for the treatment, therapy and/or prophylaxis of viral diseases and infection, including HCV infection.
    Type: Application
    Filed: December 19, 2008
    Publication date: January 12, 2012
    Applicant: Progenics Pharmaceuticals, Inc.
    Inventors: Amy Qi Han, Glen A. Coburn, Kathleen P. Provoncha, Yakov Rotshteyn
  • Publication number: 20110319418
    Abstract: Disclosed are compounds, compositions and methods for treating pain, including inflammatory, visceral, and acute pain. Such compounds are represented by Formula (I) as follows: wherein A1, L1, D, L2, and Q are defined herein.
    Type: Application
    Filed: June 27, 2011
    Publication date: December 29, 2011
    Inventors: Christopher M. Flores, Paul R. Wade
  • Publication number: 20110319414
    Abstract: The present invention provides a novel P2X3 and/or P2X2/3 receptor antagonist. A compound represented by the formula (I); wherein Ra, Rb and Rc are, (a) Ra and Rb are taken together ?Z; and Rc is a group represented by R1c; or (b) Rb and Rc are taken together to form a bond; and Ra is a group represented by —Y—R1a; R1a and R1c are each independently hydrogen, substituted or unsubstituted alkyl, etc.; R2 and R3 are each independently substituted or unsubstituted aryl, etc.; R4a and R4b are each independently hydrogen, substituted or unsubstituted alkyl, etc.; X is —N(R5)—, etc.; R5 is hydrogen, substituted or unsubstituted lower alkyl, etc.; —Y— is —O—, etc.; ?Z is ?O, etc.; and n is an integer of 0 to 4.
    Type: Application
    Filed: February 10, 2010
    Publication date: December 29, 2011
    Inventors: Hiroyuki Kai, Takayuki Kameyama, Tsuyoshi Hasegawa, MIho Oohara, Yukio Tada, Takeshi Endoh
  • Publication number: 20110237436
    Abstract: A hydrate and an anhydrous crystal form of the sodium salt of 2-iodo-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)carbamoyl]benzenesulfonamide are described. These thermodynamically stable crystal forms have particular advantages in the stability of suspension formulations.
    Type: Application
    Filed: March 2, 2011
    Publication date: September 29, 2011
    Applicant: BAYER CROPSCIENCE AG
    Inventors: Britta OLENIK, Christian WALDRAFF, Arno RATSCHINSKI, Martin-Holger HINZ, Hans-Joachim RESSEL
  • Patent number: 8013241
    Abstract: Disclosed is a novel ionic liquid gel electrolyte having high photoelectric conversion efficiency. Also disclosed are a novel dye-sensitized photoelectric conversion device using such an ionic liquid gel electrolyte, and a solar cell composed of such a dye-sensitized photoelectric conversion device. Specifically disclosed is an ionic liquid gel electrolyte obtained by gelling a liquid electrolyte by using an ionic organic oligomer gelling agent represented by the general formulae (1) and (2) below. Also specifically disclosed are a dye-sensitized photoelectric conversion device, wherein the ionic liquid gel electrolyte is arranged between a counter electrode and a dye-absorbed semiconductor substrate which is arranged in contact with a transparent conductive substrate, and a solar cell.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: September 6, 2011
    Assignee: National Institute of Advanced Industrial Science and Technology
    Inventors: Nagatoshi Koumura, Koujirou Hara, Zhong-Sheng Wang, Masaru Yoshida, Nobuyuki Tamaoki
  • Publication number: 20110137031
    Abstract: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A pyrrolopyrimidine or pyrrolotriazine derivative substituted with a carbamoyl group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
    Type: Application
    Filed: January 6, 2005
    Publication date: June 9, 2011
    Applicant: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Atsuro Nakazato, Taketoshi Okubo, Dai Nozawa, Tomoko Tamita, Ludo E.J. Kennis
  • Patent number: 7956185
    Abstract: Compounds of formula (I) where X1, C1, and D1 are defined herein, are inhibitors of polo-like kinases. The compounds of formula (I) are useful for treatment of diseases of cellular proliferation, such as, for example, cancer.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: June 7, 2011
    Assignee: Abbott Laboratories
    Inventors: Robert B. Diebold, Stevan W. Djuric, Vincent L. Giranda, Laura A. Hexamer, Nan-Horng Lin, Julie M. Miyashiro, Thomas D. Penning, Magdalena Przytulinska, Thomas J. Sowin, Gerard M. Sullivan, Zhi-Fu Tao, Yunsong Tong, Anil Vasudevan, Le Wang, Keith W. Woods, Zhiren Xia, Henry Q. Zhang